000 05513cam a2200457M 4500
001 96401
003 ES-MaUEC
005 20230102112752.0
006 m o d
007 cr |n|||||||||
008 170809s2017 sz o 000 0 eng d
020 _a3319603248
_qelectronic bk.
020 _a9783319603247
_qelectronic bk.
020 _z331960323X
020 _z9783319603230
040 _aYDX
_cYDX
_dN$T
_dGW5XE
_dEBLCP
_dN$T
_dDKU
_dOCLCF
_dUAB
_dAZU
_dUPM
_dMERER
_dOCLCQ
_dESU
_dIOG
_dCOO
_dOCLCO
_dJG0
_dOCLCO
_dOCLCA
_dES-MaUEC
_bspa
066 _c(S
050 4 _aRC700.D5
_b2017 EB
245 0 0 _aMechanisms of vascular defects in diabetes mellitus.
264 1 _aCham
_bSpringer
_c2017.
300 _a1 recurso en línea
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _atext file
_bPDF
490 0 _aAdvances in biochemistry in health and disease
_vv. 17
500 _aSpringerLink
_bSpringer Biomedical and Life Sciences eBooks 2017 English+International
505 0 _aPreface; Contents; Contributors; About the Editors; Part I: Introduction; Chapter 1: The Global Burden of Diabetes and Its Vascular Complications; 1.1 Introduction; 1.2 Global Burden of Diabetes; 1.3 Vascular Complications; 1.3.1 Microvascular Complications; 1.3.1.1 Diabetic Retinopathy (DR); 1.3.1.2 Diabetic Nephropathy; 1.3.1.3 Diabetic Neuropathy; 1.3.2 Macrovascular Complications; 1.3.2.1 Cardiovascular Disease; 1.3.2.2 Peripheral Vascular Disease; 1.3.2.3 Cerebrovascular Disease; 1.3.3 Overlap Between Micro and Macrovascular Complications
505 8 _a1.4 Mortality Due to Diabetes Associated Complications1.5 Conclusions and the Way Forward; References; Part II: Pathogenesis; Chapter 2: Genetic Basis for Increased Risk for Vascular Diseases in Diabetes; 2.1 Introduction; 2.2 Clinical Presentations of Type 2 Diabetes; 2.3 Vascular Diseases; 2.3.1 Microvascular Diseases; 2.3.2 Macrovascular Diseases; 2.4 Pathophysiology of Diabetic Complications; 2.5 Risk Assessment in the Diabetic Patient; 2.6 Risk Factors for Development of Diabetic Vascular Complications; 2.6.1 Insulin Resistance; 2.6.2 Atherogenic Dyslipidemia; 2.6.3 Hypertension
505 8 _a2.11.3 GWAS for Coronary Heart Diseases in Type 2 Diabetes2.11.3.1 Insights from GWAS for CHD; 2.12 Epigenetics and Diabetic Complications; 2.13 Conclusions; References; Chapter 3: Vascular Remodeling in Diabetes Mellitus; 3.1 Introduction; 3.2 Overview of Vascular Remodeling; 3.3 Mediators of DM Induce VRM; 3.3.1 Hyperglycemia and Related Metabolic Abnormalities; 3.3.1.1 Polyol and Hexosamine Pathway; 3.3.1.2 Diacyglycerol (DAG); 3.3.2 Advanced Glycation End Products (AGE); 3.3.2.1 Receptor Mediated Mechanisms; 3.3.2.2 Non-receptor Mediated Mechanisms; 3.3.3 Insulin Abnormalities
505 8 _a3.3.4 Excess Free Fatty Acid Production3.3.5 Increased Angiotensin II and Endothelin-1; 3.3.6 DM Associated Hyperlipidemia and Hypertension; 3.3.7 Abnormal Shear Stress; 3.4 Pathophysiological Mechanisms of Diabetes Induced Vascular Remodeling; 3.4.1 Oxidative Stress and Endothelial Dysfunction; 3.4.2 Endoplasmic Reticulum Stress and Autophagy; 3.4.3 Inflammation; 3.4.4 Vascular Calcification; 3.4.4.1 Mechanisms of Vascular Calcification; 3.4.5 Genetic and Epigenetic Effects on Diabetic VRM; 3.5 Overview of Morphological Changes in DM Induced VRM; 3.5.1 Endothelial Cell Alterations
520 3 _aThis book comprising 24 chapters is devoted to the mechanisms for the pathogenesis of the spectrum of vascular diseases in diabetes. Cellular events and molecular pathways that regulate the structure and function of both small and large arteries, the dysregulation in these vessels caused by hyperglycemia, oxidative stress, metabolic and haemostatic derangements secondary to diabetes, are discussed. Mechanisms of vascular remodelling and rupture of atherosclerotic plaques in diabetes are also covered. Several of the reviews also discuss therapeutic targets and drugs employed to reduce endothelial dysfunction and vascular inflammation in diabetes. All articles are authored by experts in their respective research fields. This compendium will be of interest to both basic scientists and clinicians in the pursuit of unravelling the molecular basis of vascular diseases and also to those who seek to identify targets for therapy of vascular complications of diabetes.
650 7 _aEnfermedades vasculares
_2embne
_0(OCoLC)fst00892225
_0
_9668848
700 1 _aKartha, C. C.
700 1 _aPillai, Radhakrishna.
700 1 _aRamachandran, Surya.
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-60324-7
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
880 8 _6505-00/(S
_a2.6.4 Elevated Plasma Glucose2.6.5 Inflammatory Mediators; 2.6.6 Homocysteine; 2.7 Approaches to Identify Genetic Factors for Diabetes; 2.8 Genetics of Type 2 Diabetes; 2.8.1 Current Status in Indian Population; 2.9 Link Between CAD and Diabetes; 2.9.1 PPARγ; 2.9.2 TCF7L2; 2.9.3 ACE (Angiotensin 1 Converting Enzyme); 2.9.4 TNF α; 2.9.5 Adiponectin; 2.9.6 IRS1; 2.9.7 Other Genes; 2.10 Genetic Factors for Coronary Heart Diseases in Type 1 Diabetes; 2.11 Genetic Factors for Coronary Heart Diseases in Type 2 Diabetes; 2.11.1 Linkage Studies; 2.11.2 Candidate Gene Studies
988 _aEBOOK, asignarmaterias, EBSPRINGER_2017D
998 _b02/2018
_dz
_e-
_zSI
999 _c96401
_d96401
_x1